• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Sarepta Therapeutics Is on Track for Further Gains

Look for an increase to the low $60s followed by the $75 area longer term.
By BRUCE KAMICH
Nov 15, 2017 | 04:02 PM EST
Stocks quotes in this article: SRPT

We last visited with Sarepta Therapeutics (SRPT) in early September, when we said, "SRPT may or may not dip to fill some of the recent gap. Aggressive traders should buy SRPT at current levels and more on strength. I am not looking to buy a pullback. Risk below $37 for now and set your sights on the October zenith."

Over the past two months SRPT has moved higher with a couple of pullbacks. Prices have not yet reached the highs of October 2016, but the charts and indicators still look bullish from my perspective.

In this daily bar chart of SRPT, below, we can see that prices are above the rising 50-day moving average line and there was a success test of the line in late October. The 200-day line also has a positive or bullish slope. The On-Balance-Volume (OBV) line shows a positive trend the past 12 months and supports the case for further gains in the weeks ahead. The Moving Average Convergence Divergence (MACD) oscillator is pointed up and has been above the zero line since late June.

In this weekly chart of SRPT, below, we can see that prices are above the rising 40-week moving average line. There is only a little resistance above the market in the $60-$64 area. The weekly OBV line is rising and is close to making a new high above the prior October high. The weekly MACD oscillator is rising in a bullish configuration.

In this Point and Figure chart of SRPT, below, we can see the uptrend and the possible upside price target of $77.71.

Bottom line: I would raise sell stops to a close below $46 and look for gains to the low $60s followed by the $75 area longer-term.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | U.S. Equity | Healthcare | How-to | Stocks

More from Healthcare

There Are Market Bright Spots, but I View the July Rally as a Head Fake

Bret Jensen
Aug 3, 2022 10:30 AM EDT

It's hard to see stock valuations rising when inflation remains high and the economy appears headed for a recession if it isn't in one already.

A Recession Appears Inevitable, but There Are Still Places to Invest

Bret Jensen
Jul 27, 2022 10:30 AM EDT

A few homebuilders and healthcare stocks seem likely to hold up better than most of the market in a recession.

Change Healthcare Continues to Knock on a Breakout Level

Bruce Kamich
Jul 25, 2022 11:25 AM EDT

The CHNG chart is at an interesting juncture.

The Healing Process Begins for Cano Health

Bruce Kamich
Jul 21, 2022 1:30 PM EDT

Here's how to approach CANO as the shares have made a bottom formation.

With HCA Healthcare, I'm Getting Healthy Indications

Bruce Kamich
Jul 21, 2022 9:20 AM EDT

The healthcare provider is set to report earnings Friday.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:24 AM EDT PETER TCHIR

    Jobs Report Reaction: Incredibly Strong, But Questions to Ask

    An incredibly strong July jobs report. Not only d...
  • 08:54 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The Secret to Dealing With FOMO
  • 03:51 PM EDT REAL MONEY

    AMD Second-Quarter Earnings Live Blog

    Real Money's Eric Jhonsa covers 's second-quarte...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login